Certains contenus de cette application ne sont pas disponibles pour le moment.
Si cette situation persiste, veuillez nous contacter àObservations et contact
1. (PH1/2016/502445) ANTIBODIES DIRECTED AGAINST CD127

Office : Philippines
Numéro de la demande : 1/2016/502445 Date de la demande : 10.06.2015
Numéro de publication : 1/2016/502445 Date de publication : 06.03.2017
Type de publication : A
Référence PCT: Numéro de la demande :PCTEP2015062993 ; Numéro de publication : Cliquer pour voir les données
CIB :
A61K 39/00
C07K 16/28
A NÉCESSITÉS COURANTES DE LA VIE
61
SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
K
PRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
39
Préparations médicinales contenant des antigènes ou des anticorps
C CHIMIE; MÉTALLURGIE
07
CHIMIE ORGANIQUE
K
PEPTIDES
16
Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
18
contre du matériel provenant d'animaux ou d'humains
28
contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Déposants : OSE IMMUNOTHERAPEUTICS
Inventeurs : VANHOVE, Bernard
POIRIER, Nicolas
MARY, Caroline
Mandataires : CRUZ MARCELO & TENEFRANCIA
Données relatives à la priorité : 15305078.6 23.01.2015 EP
62/010,117 10.06.2014 US
Titre : (EN) ANTIBODIES DIRECTED AGAINST CD127
Abrégé :
(EN) The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and/or inhibit the IL7-induced internalization of CD127. According to another aspect of the invention antibodies are provided which recognize a human CD127 epitope comprising sequences from the 2b site of CD127, in particular the epitope comprising comprises the human CD127 sequences of domain D1 and of the 2b site of CD127, in particular the epitope comprises at least one sequence from D1 comprising SEQ ID No: 115 (in particular comprising SEQ ID No: 10) and/or SEQ ID No: 111 and / or a sequence from the 2b site comprising the sequence of SEQ ID No: 116 and optionally also comprises SEQ ID No: 117 (in particular comprises SEQ ID No: 111).The antibodies of the invention are suitable for use inorder to remedy to a condition diagnosed in a human patient which results from pathogenesis related to lymphopoiesis, when IL-7 signalling pathways provide contribution to said pathogenesis, especially when an increase in the maturation, more precisely the upregulation of costimulatory molecules, of dendritic cells is undesirable.
Également publié sous:
UAa201613258SG11201610036PCA2950823AU2015273532EP3155014KR1020170019417
US20170129959IL249449CN106715471VN52585MYPI 2016002094JP2017522903
TH171839IN201617042413BR112016028755TN2016000528EA201692460RU2016151265
CR20160576WO/2015/189302